Hvsen Biotechnology Balance Sheet Health
Financial Health criteria checks 3/6
Hvsen Biotechnology has a total shareholder equity of CN¥1.4B and total debt of CN¥897.2M, which brings its debt-to-equity ratio to 63%. Its total assets and total liabilities are CN¥2.9B and CN¥1.5B respectively.
Key information
63.0%
Debt to equity ratio
CN¥897.20m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥469.58m |
| Equity | CN¥1.42b |
| Total liabilities | CN¥1.49b |
| Total assets | CN¥2.91b |
Recent financial health updates
No updates
Recent updates
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Nov 14
Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Sep 30Hvsen Biotechnology Co., Ltd. (SZSE:300871) Shares Could Be 21% Below Their Intrinsic Value Estimate
Aug 21Take Care Before Jumping Onto Hvsen Biotechnology Co., Ltd. (SZSE:300871) Even Though It's 27% Cheaper
Jun 05Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stocks Shoot Up 37% But Its P/E Still Looks Reasonable
Mar 29Financial Position Analysis
Short Term Liabilities: 300871's short term assets (CN¥1.2B) exceed its short term liabilities (CN¥893.1M).
Long Term Liabilities: 300871's short term assets (CN¥1.2B) exceed its long term liabilities (CN¥596.0M).
Debt to Equity History and Analysis
Debt Level: 300871's net debt to equity ratio (30%) is considered satisfactory.
Reducing Debt: 300871's debt to equity ratio has increased from 19.3% to 63% over the past 5 years.
Debt Coverage: 300871's debt is not well covered by operating cash flow (4.8%).
Interest Coverage: Insufficient data to determine if 300871's interest payments on its debt are well covered by EBIT.